Search hospitals > California > Torrance
Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center
Claim this profileTorrance, California 90502
Global Leader in Leukemia
Global Leader in Tumors
Conducts research for Cancer
Conducts research for Lymphoma
Conducts research for Acute Lymphoblastic Leukemia
103 reported clinical trials
8 medical researchers
Summary
Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center is a medical facility located in Torrance, California. This center is recognized for care of Leukemia, Tumors, Cancer, Lymphoma, Acute Lymphoblastic Leukemia and other specialties. Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center is involved with conducting 103 clinical trials across 294 conditions. There are 8 research doctors associated with this hospital, such as Eduard H. Panosyan, George A Karpouzas, MD, William French, MD, and Loren G Miller.Area of expertise
1Leukemia
Global LeaderStage II
Stage IV
Stage III
2Tumors
Global LeaderStage IV
Stage I
Stage II
Top PIs
Eduard H. PanosyanLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center7 years of reported clinical research
Studies Tumors
Studies Cancer
20 reported clinical trials
57 drugs studied
George A Karpouzas, MDThe Lundquist Institute at Harbor-UCLA Medical Center2 years of reported clinical research
Studies Systemic Lupus Erythematosus
Studies Lupus
6 reported clinical trials
19 drugs studied
William French, MDLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center4 years of reported clinical research
Studies Obesity
Studies Diabetes
5 reported clinical trials
6 drugs studied
Loren G MillerLundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center4 years of reported clinical research
Studies Infections
Studies Contagious Diseases
4 reported clinical trials
6 drugs studied
Clinical Trials running at Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center
Obesity
Osteosarcoma
Germ Cell Tumors
Non-Hodgkin's Lymphoma
Ovarian Tumors
Brain Tumor
Cardiovascular Disease
Testicular Carcinoma
Ovarian Carcinoma
Ovarian Choriocarcinoma
Orforglipron
for Type 2 Diabetes and Obesity
This trial is testing a new diabetes medication called orforglipron to see if it is safer and more effective than insulin in people with type 2 diabetes who are overweight or obese and at higher risk for heart problems. The study will last several years and involve multiple visits.
Recruiting2 awards Phase 3
Retatrutide
for Obesity
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.
Recruiting1 award Phase 32 criteria
Tirzepatide
for Obesity
This trial is testing tirzepatide, a medication that helps control blood sugar and reduce appetite, to see if it can lower health problems and death rates in adults who are very overweight. Tirzepatide was developed by Eli Lilly to improve blood sugar control in adults with type 2 diabetes.
Recruiting1 award Phase 39 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center?
Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center is a medical facility located in Torrance, California. This center is recognized for care of Leukemia, Tumors, Cancer, Lymphoma, Acute Lymphoblastic Leukemia and other specialties. Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center is involved with conducting 103 clinical trials across 294 conditions. There are 8 research doctors associated with this hospital, such as Eduard H. Panosyan, George A Karpouzas, MD, William French, MD, and Loren G Miller.